Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)Completed
NCT03342053Phase 2Updated Mar 24, 2022
Sponsor: Hoffmann-La Roche
Huntington's Disease
Canada, Germany, United Kingdom
NP-Supported Multidisciplinary Diabetes Management During Perioperative PeriodUnknown
NCT05293015NAUpdated Mar 23, 2022
Sponsor: Peking University Third Hospital
Diabetes
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]Completed
NCT02367794Phase 3Updated Mar 21, 2022
Sponsor: Hoffmann-La Roche
Squamous Non-Small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +21 more
Rituximab Vasculitis Maintenance StudyCompleted
NCT01697267Phase 3Updated Mar 18, 2022
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Microscopic Polyangiitis · Wegener Granulomatosis
United States, Australia, Canada, Czechia, Ireland +5 more
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCAUnknown
NCT04239196Phase 2Updated Mar 18, 2022
Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Giant Cell Arteritis · Optic Ischaemic Neuropathy
France
Sport and Self Esteem in Patients Living With HIVCompleted
NCT03920969N/AUpdated Mar 9, 2022
Sponsor: Centre Hospitalier le Mans
HIV Seropositivity
France
Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.Completed
NCT03552393Phase 2Updated Mar 7, 2022
Sponsor: Hoffmann-La Roche
Anemia · Renal Insufficiency, Chronic
United States, France, Hungary, Italy, Lithuania +2 more
Tau Protein and SV2a Imaging in Patients With Tau Protein-related DiseasesUnknown
NCT05260151N/AUpdated Mar 2, 2022
Sponsor: Xuanwu Hospital, Beijing
Alzheimer Disease · Progressive Supranuclear Palsy · Frontotemporal Dementia
China
Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)Completed
NCT05137626Phase 1Updated Feb 28, 2022
Sponsor: Atea Pharmaceuticals, Inc.
Healthy Volunteers Study
Canada
Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)Completed
NCT05004415Phase 1Updated Feb 25, 2022
Sponsor: Atea Pharmaceuticals, Inc.
Healthy Volunteer Study
United States
Bronchopulmonary PK of AT-527 (R07496998)Completed
NCT04877769Phase 1Updated Feb 25, 2022
Sponsor: Atea Pharmaceuticals, Inc.
Healthy Volunteer Study
United Kingdom
Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)Completed
NCT05154123Phase 1Updated Feb 25, 2022
Sponsor: Atea Pharmaceuticals, Inc.
Healthy Volunteer Study
Canada
Study of AT-527 in Healthy Subjects (R07496998)Completed
NCT04711187Phase 1Updated Feb 25, 2022
Sponsor: Atea Pharmaceuticals, Inc.
Healthy Volunteer Study
Canada
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic ArthritisCompleted
NCT02165345Phase 1Updated Feb 23, 2022
Sponsor: Hoffmann-La Roche
Juvenile Idiopathic Arthritis
United States, Argentina, Australia, Brazil, Canada +7 more
T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompleted
NCT02562378Phase 1Updated Feb 23, 2022
Sponsor: MedSIR
Breast Cancer
France, Spain
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaTerminated
NCT03922477Phase 1Updated Feb 21, 2022
Sponsor: Hoffmann-La Roche
Acute Myeloid Leukemia
United States
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCLCompleted
NCT02987400Phase 2Updated Feb 16, 2022
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Lymphoma, Large B-Cell, Diffuse
Austria
PROOF-Registry New and Extended Belgium -LuxembourgCompleted
NCT03732859N/AUpdated Feb 15, 2022
Sponsor: Belgian Thoracic Society
Idiopathic Pulmonary Fibrosis
Belgium, Luxembourg
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 PneumoniaCompleted
NCT04409262Phase 3Updated Feb 14, 2022
Sponsor: Hoffmann-La Roche
COVID-19 Pneumonia
United States, Brazil, Russia, Spain
The Effect of Hepatic Impairment on the Pharmacokinetics of BalovaptanWithdrawn
NCT03912350Phase 1Updated Feb 8, 2022
Sponsor: Hoffmann-La Roche
Autism Spectrum Disorder
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)Completed
NCT02861014Phase 3Updated Jan 27, 2022
Sponsor: Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
Australia, Belgium, Czechia, Denmark, Estonia +12 more
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6Completed
NCT03255096Phase 1Updated Jan 24, 2022
Sponsor: Hoffmann-La Roche
Diffuse Large B-cell Lymphoma · High-Grade B-cell Lymphoma
United States, Australia, Denmark, Spain
A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic SettingCompleted
NCT03589105Phase 4Updated Jan 11, 2022
Sponsor: Hoffmann-La Roche
Multiple Sclerosis
France
A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)Terminated
NCT02545283Phase 3Updated Jan 11, 2022
Sponsor: Hoffmann-La Roche
Leukemia, Myeloid, Acute
United States, Australia, Austria, Belgium, Canada +14 more
Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell TransplantationTerminated
NCT03153514Phase 2Updated Jan 5, 2022
Sponsor: German CLL Study Group
Chronic Lymphocytic Leukemia · Richter's Transformation
Germany

Previous page Next page